IL134936A0 - Genetically modified tumor-targeted bacteria with reduced virulence - Google Patents

Genetically modified tumor-targeted bacteria with reduced virulence

Info

Publication number
IL134936A0
IL134936A0 IL13493698A IL13493698A IL134936A0 IL 134936 A0 IL134936 A0 IL 134936A0 IL 13493698 A IL13493698 A IL 13493698A IL 13493698 A IL13493698 A IL 13493698A IL 134936 A0 IL134936 A0 IL 134936A0
Authority
IL
Israel
Prior art keywords
genetically modified
modified tumor
targeted bacteria
reduced virulence
virulence
Prior art date
Application number
IL13493698A
Other languages
English (en)
Original Assignee
Vion Pharmaceuticals Inc
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/926,636 external-priority patent/US6080849A/en
Application filed by Vion Pharmaceuticals Inc, Univ Yale filed Critical Vion Pharmaceuticals Inc
Publication of IL134936A0 publication Critical patent/IL134936A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/879—Salmonella

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL13493698A 1997-09-10 1998-09-09 Genetically modified tumor-targeted bacteria with reduced virulence IL134936A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/926,636 US6080849A (en) 1997-09-10 1997-09-10 Genetically modified tumor-targeted bacteria with reduced virulence
US09/149,832 US6447784B1 (en) 1997-09-10 1998-09-08 Genetically modified tumor-targeted bacteria with reduced virulence
PCT/US1998/018701 WO1999013053A1 (en) 1997-09-10 1998-09-09 Genetically modified tumor-targeted bacteria with reduced virulence

Publications (1)

Publication Number Publication Date
IL134936A0 true IL134936A0 (en) 2001-05-20

Family

ID=26847071

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13493698A IL134936A0 (en) 1997-09-10 1998-09-09 Genetically modified tumor-targeted bacteria with reduced virulence

Country Status (11)

Country Link
US (2) US6863894B2 (zh)
EP (1) EP1012232B1 (zh)
JP (1) JP2002500001A (zh)
CN (1) CN1253551C (zh)
AU (1) AU749695B2 (zh)
BR (1) BR9812079A (zh)
CA (1) CA2302866C (zh)
HK (1) HK1033956A1 (zh)
IL (1) IL134936A0 (zh)
NZ (1) NZ503376A (zh)
WO (1) WO1999013053A1 (zh)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4723041A (en) * 1985-09-24 1988-02-02 Catalytica Associates Olefin oxidation catalyst system
US4720474A (en) * 1985-09-24 1988-01-19 Catalytica Associates Olefin oxidation catalyst system
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
IL134936A0 (en) 1997-09-10 2001-05-20 Vion Pharmaceuticals Inc Genetically modified tumor-targeted bacteria with reduced virulence
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
BR0014491A (pt) * 1999-10-04 2004-03-09 Vion Pharmaceuticals Inc Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusão
WO2001025399A2 (en) * 1999-10-04 2001-04-12 Vion Pharmaceuticals, Inc. Non-invasive tumor imaging by tumor-targeted bacteria
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
EP1267913A2 (en) * 1999-11-12 2003-01-02 EntreMed, Inc. Methods for administration of therapeutic agents on an antiangiogenic schedule
CA2342040C (en) * 2000-09-21 2012-07-10 Kyowa Hakko Kogyo Co., Ltd. Anaerobic bacterium as a drug for cancer gene therapy
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US7396822B2 (en) 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
WO2003063593A1 (en) * 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
EP1654364A4 (en) * 2003-08-13 2008-02-13 Novartis Vaccines & Diagnostic CURRENT HOST CELL RELEASE COMPRISING POLYNUCLEOTIDES ENCODING IMMUNOGENS
US20070298012A1 (en) * 2003-12-16 2007-12-27 Ivan King Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
CN100435850C (zh) * 2004-03-22 2008-11-26 中国医学科学院血液学研究所 具有放射保护和抗肿瘤作用的减毒沙门氏菌药物组合物
AU2005251397B2 (en) * 2004-06-07 2010-11-11 Qu Biologics Inc. Bacterial compositions for the treatment of cancer
SG158077A1 (en) 2004-11-24 2010-01-29 Anaeropharma Science Inc Novel shuttle vector
CA2603453C (en) * 2005-04-08 2015-01-27 Yoshinori Hamaji 5-fluorouracil-resistant bacteria and method for production thereof
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US7998461B2 (en) * 2007-11-15 2011-08-16 University Of Massachusetts Salmonella cancer therapeutics and related therapeutic methods
EP2242516A1 (en) 2008-01-11 2010-10-27 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
US8647642B2 (en) * 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
WO2010062982A1 (en) * 2008-11-26 2010-06-03 Vion Pharmaceuticals, Inc. Tumor-targeting co2-resistant salmonella
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
WO2010141143A2 (en) * 2009-04-21 2010-12-09 Vivocure, Inc. Engineered avirulent bacteria strains and use in medical treatments
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
EP2593796A4 (en) 2010-07-16 2016-07-27 Auckland Uniservices Ltd BACTERIAL NITROREDUCTASE ENZYMES AND ASSOCIATED METHODS
AU2012217728B2 (en) 2011-02-15 2017-04-27 Vaxiion Therapeutics, Llc Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
EP2764119A2 (en) 2011-10-05 2014-08-13 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013128288A1 (en) 2012-02-27 2013-09-06 Thelial Technologies S.A. Monomeric bacterial actin adp-ribosyltransferases as cancer chemotherapeutics
US9127284B2 (en) 2012-05-04 2015-09-08 The University Of Hong Kong Modified bacteria and their uses thereof for the treatment of cancer or tumor
DK2941258T3 (da) 2013-01-02 2019-12-16 Decoy Biosystems Inc Sammensætninger og fremgangsmåder til behandling af cancer ved anvendelse af bakterier
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
CN103656684B (zh) * 2013-12-03 2016-02-24 南京华贞生物医药科技有限公司 减毒鼠伤寒沙门氏菌及其基因工程菌在制备治疗胰腺癌的药物上的应用
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11168326B2 (en) 2017-07-11 2021-11-09 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3176812A1 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2020132980A1 (zh) * 2018-12-26 2020-07-02 深圳先进技术研究院 细菌-光热纳米颗粒复合物及制备方法和应用
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
JP2022524951A (ja) 2019-02-27 2022-05-11 アクティム・セラピューティクス・インコーポレイテッド 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
MX2022005705A (es) 2019-11-12 2022-08-16 Actym Therapeutics Inc Plataformas de suministro bacteriano inmunomoduladoras y su uso para el suministro de productos terapéuticos.
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
JP2023539454A (ja) 2020-08-12 2023-09-14 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム
EP4429682A2 (en) 2021-11-09 2024-09-18 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
CN117305155B (zh) * 2023-08-28 2024-07-05 江苏省家禽科学研究所 一种抑制沙门氏菌毒力因子的方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US29043A (en) * 1860-07-10 Improvement in cultivators
JPS57142256A (en) 1981-02-25 1982-09-02 Kao Corp Sanitary napkin
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
EP0142641B1 (de) * 1983-09-26 1991-01-16 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
CA1321962C (en) 1985-03-20 1993-09-07 Aizo Matsushiro Dental caries preventive preparations and method for preparing said preparations
JPH0696538B2 (ja) 1985-12-19 1994-11-30 株式会社アドバンス 抗発癌剤
JPS62298657A (ja) 1986-06-16 1987-12-25 Diesel Kiki Co Ltd 燃料噴射弁
JPH0761950B2 (ja) 1986-10-17 1995-07-05 塩野義製薬株式会社 抗腫瘍剤
DE3735381A1 (de) 1987-03-31 1989-05-03 Boehringer Mannheim Gmbh Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
JPH01180830A (ja) 1988-01-11 1989-07-18 Kayaku:Kk 抗腫瘍剤
EP0338679A3 (en) 1988-03-24 1991-03-06 Genentech, Inc. Tumour necrosis factor in the treatment of bladder cancer
JPH0284172A (ja) 1988-07-21 1990-03-26 Smithkline Beckman Corp 異種遺伝子の発現能を有し、組換え型ワクチンとして有用なサルモネラ形質転換体
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
JPH0376580A (ja) 1989-08-17 1991-04-02 Japan Tobacco Inc 大腸菌発現ベクターとそれを利用した抗ウイルス性タンパク質の製造方法
JPH05504331A (ja) 1989-11-03 1993-07-08 ワシントン ユニバーシティ 交差防護サルモネラワクチン類
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5695983A (en) 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
EP0563311B1 (en) 1990-12-18 2000-03-15 The General Hospital Corporation Improved vaccines
ES2131069T3 (es) 1991-03-05 1999-07-16 Wellcome Found Expresion de proteinas recombinantes en bacterias atenuadas.
IL101409A0 (en) * 1992-03-29 1992-11-15 Era Masis Ltd Method for the early diagnosis of cancer
IL101410A0 (en) 1992-03-29 1992-11-15 Era Masis Ltd Formulation for the treatment of cancer
WO1995005832A1 (fr) 1993-08-25 1995-03-02 Otsuka Pharmaceutical Factory, Inc. Analeptique des fonctions cardiaques
EP0722343A4 (en) 1993-10-06 1999-12-29 Us Gov Health & Human Serv TREATMENT OF TUMORS BY GENETIC TRANSFORMATION OF TUMOR CELLS USING GENES ENCODING NEGATIVE SELECTIVE MARKERS AND CYTOKINES
IT1270123B (it) 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US6150170A (en) 1998-05-03 2000-11-21 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
JP2000500734A (ja) 1995-09-06 2000-01-25 アメリカ合衆国 細菌送達系
US5824538A (en) * 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
EP0939761A4 (en) 1995-11-14 2002-07-31 Gen Hospital Corp SALMONELLA SECRETIED PROTEINS AND USE THEREOF
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US6887483B2 (en) 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
WO1997025061A1 (en) 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria
US6025417A (en) 1996-02-28 2000-02-15 Biotechnology Research & Development Corp. Biodegradable polyester compositions with natural polymers and articles thereof
NZ332719A (en) 1996-05-10 2000-01-28 Upjohn Co Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
EP0973911A1 (en) 1997-01-30 2000-01-26 Imperial College Of Science, Technology & Medicine MUTANT $i(msbB) or $i(htrB) GENES
AU6428998A (en) 1997-03-11 1998-09-29 Kent Nilsson Device for avoiding whiplash injuries
WO1998044131A1 (en) 1997-03-28 1998-10-08 Walter Reed Army Institute Of Research Antimicrobial mediated bacterial dna delivery
US6537558B2 (en) 1997-03-31 2003-03-25 Megan Health, Inc. Methods of producing and using virulence attenuated poxR mutant bacteria
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
IL134936A0 (en) 1997-09-10 2001-05-20 Vion Pharmaceuticals Inc Genetically modified tumor-targeted bacteria with reduced virulence
US6593592B1 (en) 1999-01-29 2003-07-15 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device having thin film transistors
BR0014491A (pt) 1999-10-04 2004-03-09 Vion Pharmaceuticals Inc Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusão
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors

Also Published As

Publication number Publication date
US6863894B2 (en) 2005-03-08
EP1012232A1 (en) 2000-06-28
JP2002500001A (ja) 2002-01-08
CN1253551C (zh) 2006-04-26
AU9380798A (en) 1999-03-29
HK1033956A1 (en) 2001-10-05
US20050255088A1 (en) 2005-11-17
US20030109026A1 (en) 2003-06-12
NZ503376A (en) 2002-10-25
EP1012232A4 (en) 2005-01-19
CA2302866A1 (en) 1999-03-18
CN1278864A (zh) 2001-01-03
CA2302866C (en) 2012-02-21
EP1012232B1 (en) 2009-10-28
AU749695B2 (en) 2002-07-04
US7354592B2 (en) 2008-04-08
BR9812079A (pt) 2000-09-26
WO1999013053A1 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
IL134936A0 (en) Genetically modified tumor-targeted bacteria with reduced virulence
HU9303093D0 (en) Enzyme systhems
EP1010754A4 (en) New microorganism
AU3243595A (en) Genetically engineered swine cells
GB9601333D0 (en) Microencapsulated genetically engineered microorganisms for clinical application
ZA98387B (en) Novel microorganisms.
GB9615426D0 (en) Transfer structure
GB9410805D0 (en) Biosensors
GB2273980B (en) Dyeliquor heating arrangement
GB9023735D0 (en) Bacterial strain
ZA982733B (en) Bacterial plasmids
GB9300124D0 (en) Bacterial strain
GB9315183D0 (en) Biosensors
GB9308734D0 (en) Viable bacteria
IL136266A0 (en) Chemoprotective bacterial strains
GB2301592B (en) Luciferases
GB9407484D0 (en) Enzyme
GB9422157D0 (en) Enzyme
EP1037969A4 (en) FIBRINOGEN CONVERSING ENZYME HYBRID
GB9715702D0 (en) Bacterial isolate
GB2316684B (en) Degradatrive bacteria
GB9405750D0 (en) Luciferases
ZA982196B (en) Cercosporin-degrading bacteria
ZA9710689B (en) Colorant stabilizers
GB9408590D0 (en) Enzymes